Ocrelizumab
Evidence-based neurology checklist on ocrelizumab: Mode of action Ocrelizumab is a second generation humanised anti CD20 antibody It depletes B cells Indications Benefits in primary progressive MS Intravenous administration Subcutaneous administration Neurological side effects Infectious side…
Mode of action
- Ocrelizumab is a second generation humanised anti CD20 antibody
- It depletes B cells
Indications
Benefits in primary progressive MS
Intravenous administration
Subcutaneous administration
Neurological side effects
Infectious side effects
Systemic side effects
Obstetric aspects
Precautions
Withdrawal
References
- Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 2016; 9:44-52.
- Montalban X, Hauser SL, Kappos L, et al; ORATORIO Clinical Investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017; 376:209-220.
- Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011; 378:1779-1787.
- Hauser SL, Bar-Or A, Comi G, et al; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017; 376:221-234.
- Barkhof F, Kappos L, Wolinsky JS, et al. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. Neurology 2019; doi: 10.1212/WNL.0000000000008189 (Epub ahead of print).
- And 24 more. Subscribe to see the full list
